| U.S. Brand Names |
| Otrivin® Nasal [OTC] |
 |
| Generic Available |
|
Yes |
|
| Synonyms |
| Xylometazoline Hydrochloride |
|
| Pharmacological Index |
|
Ophthalmic Agent, Vasoconstrictor |
|
| Use |
|
Symptomatic relief of nasal and nasopharyngeal mucosal congestion |
|
| Pregnancy Risk Factor |
|
C |
|
| Adverse Reactions |
|
1% to 10%: Central nervous system: Drowsiness, dizziness, seizures, headache Ocular: Blurred vision, ocular irritation, photophobia Miscellaneous: Sweating |
|
| Drug Interactions |
|
No data reported |
|
| Mechanism of Action |
|
Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction |
|
| Pharmacodynamics/Kinetics |
|
Onset of action: Intranasal: Local vasoconstriction occurs within 5-10 minutes Duration: 5-6 hours |
|
| Usual Dosage |
|
Children 2-12 years: Instill 2-3 drops (0.05%) in each nostril every 8-10 hours Children >12 years and Adults: Instill 2-3 drops or sprays (0.1%) in each nostril every 8-10 hours |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Do not exceed recommended dosage; do not use for more than 4 consecutive days |
|
| Nursing Implications |
|
Do not exceed recommended dosage; do not use for more than 4 consecutive days |
|
| Dosage Forms |
|
Solution, nasal, as hydrochloride: 0.05% [0.5 mg/mL] (20 mL); 0.1% [1 mg/mL] (15 mL, 20 mL) |
|
|
Copyright © 2007 Drugs Area |
